Disease · MONDO_0021063

malignant colon neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. malignant colon neoplasm. Diseases, record MONDO_0021063. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021063

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: malignant colon neoplasm; Open Targets
Open Targets ID: MONDO_0021063; Open Targets
Other names: cancer of colon, colon cancer, colon neoplasm, malignant, colon tumor, malignant, malignant colon tumor, malignant colon tumour, malignant colonic neoplasm, malignant colonic tumor, malignant colonic tumour, malignant neoplasm of colon, malignant neoplasm of the colon, malignant tumor of colon, malignant tumor of the colon, malignant tumour of colon, malignant tumour of the colon; Open Targets
Disease Ontology: DOID:219; Disease Ontology
NCI Thesaurus: C9242; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 144 drugs, from PMDA and TTD; Open Targets

Drugs144

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
OXALIPLATIN	CHEMBL414804	Small molecule	Approval	PMDA	87	86	73	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Approval	TTD	71	70	57	Drugs and targets
LEUCOVORIN	CHEMBL1679	Small molecule	Approval	TTD	25	24	17	Drugs and targets
LEVAMISOLE	CHEMBL1454	Small molecule	Approval	TTD, at withdrawal	2	1	1	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 3	ClinicalTrials.gov	57	57	51	Drugs and targets
LEUCOVORIN CALCIUM	CHEMBL1201138	Small molecule	Phase 3	ClinicalTrials.gov	30	30	23	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 3	ClinicalTrials.gov	25	25	18	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 3	ClinicalTrials.gov	16	16	16	Drugs and targets
FOLINIC ACID	CHEMBL1232801	Small molecule	Phase 3	ClinicalTrials.gov	12	12	6	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets

1 to 10 of 144

See all 144 drugs

Targets232

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	10	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
KDR	Vascular endothelial growth factor receptor	7	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	6	Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	5	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
MAP2K1	Dual specificity mitogen-activated protein kinase kinase 1	5	Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 3	https://conductscience.org/library/genes/5604	Drugs and targets
MAP2K2	Dual specificity mitogen-activated protein kinase kinase 2	5	Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor	Phase 3	https://conductscience.org/library/genes/5605	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	5	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
TYMS	Thymidylate synthase	5	Thymidylate synthase inhibitor	Approval	https://conductscience.org/library/genes/7298	Drugs and targets
ABL1	Bcr/Abl fusion protein	4	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 3	https://conductscience.org/library/genes/25	Drugs and targets

1 to 10 of 232

See all 232 targets

Trials220

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 14 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00079274	Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer	Phase 3	3,397	2015-02-09	Adenocarcinoma of the Colon, Stage III Colon Cancer	CETUXIMAB, FLUOROURACIL, IRINOTECAN HYDROCHLORIDE, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01150045	Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery	Phase 3	2,527	2021-08-06	Colorectal Cancer	CELECOXIB, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00217737	Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer	Phase 3	2,431	2025-07-20	Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7	BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00009737	A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer	Phase 3	1,987	2016-06-22	Colorectal Cancer	CAPECITABINE, FLUOROURACIL, LEUCOVORIN CALCIUM	Its record names the disease	ClinicalTrials.gov
NCT00069121	A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer	Phase 3	1,886	2011-07-29	Colorectal Cancer	CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT00002525	Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed	Phase 3	859	2016-07-20	Colorectal Cancer	FLUOROURACIL, LEUCOVORIN CALCIUM	Its record names the disease	ClinicalTrials.gov
NCT04068103	Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery	Phase 2/3	635	2025-04-27	Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8	CAPECITABINE, FLUOROURACIL, LEUCOVORIN CALCIUM, OXALIPLATIN	Its record names the disease	ClinicalTrials.gov
NCT01664494	An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer		563	2016-05-02	Breast Cancer, Colorectal Cancer, Gastric Cancer	CAPECITABINE	Its record names the disease	ClinicalTrials.gov
NCT01830621	BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Pretreated Advanced Colorectal Carcinoma	Phase 3	282	2019-03-11	Colorectal Carcinoma	NAPABUCASIN	Its record names the disease	ClinicalTrials.gov
NCT01876511	Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)	Phase 2	113	2020-01-07	MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 220

See all 220 trials

Comparisons in its trials14

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Capecitabine vs 5-Fluorouracil + Leucovorin: Relapse-Free Survival	677 of 1,004	621 of 983	1,987	NCT00009737	Trial comparisons
Capecitabine vs 5-Fluorouracil + Leucovorin: Disease-free Survival	656 of 1,004	603 of 983	1,987	NCT00009737	Trial comparisons
Capecitabine vs 5-Fluorouracil + Leucovorin: Overall Survival	804 of 1,004	756 of 983	1,987	NCT00009737	Trial comparisons
Capecitabine vs 5-Fluorouracil + Leucovorin: serious adverse events	181 of 995	182 of 974	1,969	NCT00009737	Trial comparisons
Arm I (Blood Stored and Tested for ctDNA Later) vs Arm II (Blood Tested for ctDNA at Baseline): deaths from any cause	8 of 318	6 of 317	635	NCT04068103	Trial comparisons
BBI608 vs Placebo: Disease Control Rate	17 of 138	18 of 144	282	NCT01830621	Trial comparisons
BBI608 vs Placebo: Number of Patients With Adverse Events	135 of 136	139 of 144	280	NCT01830621	Trial comparisons
BBI608 vs Placebo: deaths from any cause	127 of 136	130 of 144	280	NCT01830621	Trial comparisons
BBI608 vs Placebo: serious adverse events	40 of 136	29 of 144	280	NCT01830621	Trial comparisons
XELOX + Bevacizumab vs XELIRI + Bevacizumab: Number of Participants With Serious Adverse Events (SAEs)	9 of 34	11 of 31	65	NCT00127036	Trial comparisons

1 to 10 of 14

See all 14 comparisons in its trials

Papers from its trials179

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39036382	RESULT	1	PubMed
39035212	RESULT	1	PubMed
38564700	RESULT	3	PubMed
38431733	RESULT	1	PubMed
36931243	RESULT	1	PubMed
36657089	RESULT	3	PubMed
36633525	RESULT	1	PubMed
35660797	RESULT	1	PubMed
35427471	RESULT	1	PubMed
35118423	RESULT	1	PubMed

1 to 10 of 179

See all 179 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021063

GET https://conductscience.org/api/diseases/v1/MONDO_0021063/drugs?page=2

API reference For AI assistants